Celgene Corp (CELG) 118.47 $CELG Pioneer Fundam
Post# of 64074
Posted On: 03/03/2015 7:55:59 PM
Celgene Corp (CELG) 118.47 $CELG
Pioneer Fundamental Growth Fund: Why Is It Revving Up?
at Investor's Business Daily - 1 hr 5 mins ago
Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals...
SBUX: 94.00 (-0.22), ESRX: 84.35 (-0.58), LNKD: 265.54 (-3.88), GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), AAPL: 129.36 (+0.27), CELG: 118.47 (-1.84)
Celgene's Abraxane Combination Therapy Cleared in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 22 mins ago
Celgene Corporation's (CELG) Abraxane was approved in the EU in combination with carboplatin for the first-line treatment of NSCLC
CYTK: 7.97 (+0.10), LLY: 70.37 (-0.75), AFFX: 11.74 (-0.04), CELG: 118.47 (-1.84)
Final Glance: Biotechnology companies
AP - 1 hr 49 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - 2 hrs 50 mins ago
BIIB: 412.79 (-3.00), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84), GSK: 47.71 (-0.22), BMY: 61.92 (-0.38), HSP: 87.71 (+0.04), NVS: 99.06 (-1.01), CELG: 118.47 (-1.84)
Stock Markets Take a Breather After Monday's Record Run
at The Street - Tue Mar 03, 3:11PM CST
Stocks took a break from smashing records and hitting multi-year highs on Tuesday.
BCS: 15.66 (-0.42), PSX: 78.09 (+1.09), F: 16.17 (-0.40), DKS: 56.00 (+0.58), PFE: 34.56 (-0.21), C: 53.73 (+0.24), MYL: 55.44 (-2.45), BBY: 39.18 (+0.55), COP: 64.78 (+0.38), LL: 40.78 (+1.95), XLV: 72.23 (-0.66), CELG: 118.47 (-1.84), AZO: 651.90 (+2.37), TOT: 53.09 (+0.24), GILD: 102.79 (-1.04), TGT: 78.00 (+0.32), LEAF: 50.23 (+12.19), GM: 37.80 (+0.19), BP: 41.74 (+0.44), XLE: 78.76 (+0.29), BABA: 81.58 (-2.42)
Stocks Recover From Lows After Crude Oil Jumps Over $50
at The Street - Tue Mar 03, 2:22PM CST
Stocks move off session lows by mid-afternoon Tuesday, buoyed by a rally in oil prices.
BCS: 15.66 (-0.42), F: 16.17 (-0.40), GE: 25.86 (-0.25), DKS: 56.00 (+0.58), PFE: 34.56 (-0.21), C: 53.73 (+0.24), MYL: 55.44 (-2.45), BBY: 39.18 (+0.55), LL: 40.78 (+1.95), XLV: 72.23 (-0.66), CELG: 118.47 (-1.84), AZO: 651.90 (+2.37), GILD: 102.79 (-1.04), GM: 37.80 (+0.19), LEAF: 50.23 (+12.19), BABA: 81.58 (-2.42)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 384.61 (-1.04), BIIB: 412.79 (-3.00), FB: 79.60 (-0.15), AMGN: 158.56 (-1.07), H: 61.26 (-0.50), INTC: 34.10 (+0.04), PCLN: 1,242.03 (-7.37), CELG: 118.47 (-1.84), SBUX: 94.00 (-0.22), GILD: 102.79 (-1.04), MSFT: 43.28 (-0.60), AAPL: 129.36 (+0.27), CSCO: 29.54 (-0.65), ONNN: 12.87 (-0.29)
Stocks Slip From Highs; Mylan Pulls Health Care Sector Lower
at The Street - Tue Mar 03, 10:28AM CST
Stocks fall back from records on Tuesday morning.
BCS: 15.66 (-0.42), MDR: 3.33 (+0.72), F: 16.17 (-0.40), GE: 25.86 (-0.25), DKS: 56.00 (+0.58), PFE: 34.56 (-0.21), C: 53.73 (+0.24), MYL: 55.44 (-2.45), BBY: 39.18 (+0.55), LL: 40.78 (+1.95), CELG: 118.47 (-1.84), AZO: 651.90 (+2.37), GILD: 102.79 (-1.04), GM: 37.80 (+0.19), LEAF: 50.23 (+12.19)
Ligand Pharmaceuticals Weakens The Bear Case
Trevor Lowenthal - at Seeking Alpha - Tue Mar 03, 10:17AM CST
LGND: 66.45 (+2.87), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Midday Glance: Biotechnology companies
AP - Mon Mar 02, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Early Glance: Biotechnology companies
AP - Mon Mar 02, 10:16AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Abraxane expanded label cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 9:47AM CST
CELG: 118.47 (-1.84)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 102.34 (-0.88), BIIB: 412.79 (-3.00), ACAD: 38.14 (-0.09), SPY: 211.12 (-0.87), PCYC: 216.76 (-4.53), GILD: 102.79 (-1.04), MRK: 58.34 (-0.24), ALXN: 182.51 (-2.11), IBB: 337.92 (-1.83), CELG: 118.47 (-1.84)
ABRAXANE(R) Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
Business Wire - Mon Mar 02, 8:45AM CST
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved ABRAXANE(R) (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
CELG: 118.47 (-1.84), CELGZ: 3.23 (+0.06)
Amgen's Long Case Strengthens After Kyprolis Data
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 7:41AM CST
AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 01, 6:12AM CST
Source: Celgene Corporation Gilead Sciences ' blockbuster launches of the hepatitis C drugs Sovaldi and Harvoni resulted in its revenue jumping 122% in 2014, but with Gilead Sciences facing tough comparisons this year, these three big-cap biotech...
JNJ: 102.34 (-0.88), BIIB: 412.79 (-3.00), PCYC: 216.76 (-4.53), GILD: 102.79 (-1.04), CELG: 118.47 (-1.84)
Biotech Celgene Thrives On Life-Giving Drugs
at Investor's Business Daily - Fri Feb 27, 5:51PM CST
Celgene is a company built on a premise that would make most corporate executives shudder. The premise: find applicable uses for derivatives of thalidomide, a drug banned by the FDA in 1961 after causing tens of thousands of birth defects. But the...
CELG: 118.47 (-1.84)
Pioneer Fundamental Growth Fund: Why Is It Revving Up?
at Investor's Business Daily - 1 hr 5 mins ago
Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals...
SBUX: 94.00 (-0.22), ESRX: 84.35 (-0.58), LNKD: 265.54 (-3.88), GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), AAPL: 129.36 (+0.27), CELG: 118.47 (-1.84)
Celgene's Abraxane Combination Therapy Cleared in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 22 mins ago
Celgene Corporation's (CELG) Abraxane was approved in the EU in combination with carboplatin for the first-line treatment of NSCLC
CYTK: 7.97 (+0.10), LLY: 70.37 (-0.75), AFFX: 11.74 (-0.04), CELG: 118.47 (-1.84)
Final Glance: Biotechnology companies
AP - 1 hr 49 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - 2 hrs 50 mins ago
BIIB: 412.79 (-3.00), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84), GSK: 47.71 (-0.22), BMY: 61.92 (-0.38), HSP: 87.71 (+0.04), NVS: 99.06 (-1.01), CELG: 118.47 (-1.84)
Stock Markets Take a Breather After Monday's Record Run
at The Street - Tue Mar 03, 3:11PM CST
Stocks took a break from smashing records and hitting multi-year highs on Tuesday.
BCS: 15.66 (-0.42), PSX: 78.09 (+1.09), F: 16.17 (-0.40), DKS: 56.00 (+0.58), PFE: 34.56 (-0.21), C: 53.73 (+0.24), MYL: 55.44 (-2.45), BBY: 39.18 (+0.55), COP: 64.78 (+0.38), LL: 40.78 (+1.95), XLV: 72.23 (-0.66), CELG: 118.47 (-1.84), AZO: 651.90 (+2.37), TOT: 53.09 (+0.24), GILD: 102.79 (-1.04), TGT: 78.00 (+0.32), LEAF: 50.23 (+12.19), GM: 37.80 (+0.19), BP: 41.74 (+0.44), XLE: 78.76 (+0.29), BABA: 81.58 (-2.42)
Stocks Recover From Lows After Crude Oil Jumps Over $50
at The Street - Tue Mar 03, 2:22PM CST
Stocks move off session lows by mid-afternoon Tuesday, buoyed by a rally in oil prices.
BCS: 15.66 (-0.42), F: 16.17 (-0.40), GE: 25.86 (-0.25), DKS: 56.00 (+0.58), PFE: 34.56 (-0.21), C: 53.73 (+0.24), MYL: 55.44 (-2.45), BBY: 39.18 (+0.55), LL: 40.78 (+1.95), XLV: 72.23 (-0.66), CELG: 118.47 (-1.84), AZO: 651.90 (+2.37), GILD: 102.79 (-1.04), GM: 37.80 (+0.19), LEAF: 50.23 (+12.19), BABA: 81.58 (-2.42)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 384.61 (-1.04), BIIB: 412.79 (-3.00), FB: 79.60 (-0.15), AMGN: 158.56 (-1.07), H: 61.26 (-0.50), INTC: 34.10 (+0.04), PCLN: 1,242.03 (-7.37), CELG: 118.47 (-1.84), SBUX: 94.00 (-0.22), GILD: 102.79 (-1.04), MSFT: 43.28 (-0.60), AAPL: 129.36 (+0.27), CSCO: 29.54 (-0.65), ONNN: 12.87 (-0.29)
Stocks Slip From Highs; Mylan Pulls Health Care Sector Lower
at The Street - Tue Mar 03, 10:28AM CST
Stocks fall back from records on Tuesday morning.
BCS: 15.66 (-0.42), MDR: 3.33 (+0.72), F: 16.17 (-0.40), GE: 25.86 (-0.25), DKS: 56.00 (+0.58), PFE: 34.56 (-0.21), C: 53.73 (+0.24), MYL: 55.44 (-2.45), BBY: 39.18 (+0.55), LL: 40.78 (+1.95), CELG: 118.47 (-1.84), AZO: 651.90 (+2.37), GILD: 102.79 (-1.04), GM: 37.80 (+0.19), LEAF: 50.23 (+12.19)
Ligand Pharmaceuticals Weakens The Bear Case
Trevor Lowenthal - at Seeking Alpha - Tue Mar 03, 10:17AM CST
LGND: 66.45 (+2.87), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Midday Glance: Biotechnology companies
AP - Mon Mar 02, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Early Glance: Biotechnology companies
AP - Mon Mar 02, 10:16AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Abraxane expanded label cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 9:47AM CST
CELG: 118.47 (-1.84)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 102.34 (-0.88), BIIB: 412.79 (-3.00), ACAD: 38.14 (-0.09), SPY: 211.12 (-0.87), PCYC: 216.76 (-4.53), GILD: 102.79 (-1.04), MRK: 58.34 (-0.24), ALXN: 182.51 (-2.11), IBB: 337.92 (-1.83), CELG: 118.47 (-1.84)
ABRAXANE(R) Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
Business Wire - Mon Mar 02, 8:45AM CST
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved ABRAXANE(R) (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
CELG: 118.47 (-1.84), CELGZ: 3.23 (+0.06)
Amgen's Long Case Strengthens After Kyprolis Data
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 7:41AM CST
AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 01, 6:12AM CST
Source: Celgene Corporation Gilead Sciences ' blockbuster launches of the hepatitis C drugs Sovaldi and Harvoni resulted in its revenue jumping 122% in 2014, but with Gilead Sciences facing tough comparisons this year, these three big-cap biotech...
JNJ: 102.34 (-0.88), BIIB: 412.79 (-3.00), PCYC: 216.76 (-4.53), GILD: 102.79 (-1.04), CELG: 118.47 (-1.84)
Biotech Celgene Thrives On Life-Giving Drugs
at Investor's Business Daily - Fri Feb 27, 5:51PM CST
Celgene is a company built on a premise that would make most corporate executives shudder. The premise: find applicable uses for derivatives of thalidomide, a drug banned by the FDA in 1961 after causing tens of thousands of birth defects. But the...
CELG: 118.47 (-1.84)
(0)
(0)Scroll down for more posts ▼